Compound class:
Synthetic organic
Comment: OPS-2071 is a fluoroquinolone antibacterial compound, with broad-spectrum activity against both Gram-positive and Gram-negative bacteria [2]. It is a clinical candidate being developed by Otsuka Pharmaceutical (Tokyo, Japan) as a treatment for intestinal infections, particularly those caused by Clostridioides difficile. Functionally, it is a type II DNA topoisomerase inhibitor with similar activity against DNA gyrase and DNA topoisomerase 4 [1].
|
|
Bioactivity Comments |
The MIC90 for antibacterial activity against a panel of clinical isolates of C. difficile is 0.5 μg/ml [2]. |